Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
E: timothy.power@bms.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
stocks
5 undervalued US stocks that crushed earnings
Names like Sony and GSK are still cheap despite impressive earnings beats for Q2 2024.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,767.90 | 28.10 | -0.32% |
| CAC 40 | 7,765.11 | 10.79 | -0.14% |
| DAX 40 | 23,771.45 | 177.45 | -0.74% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,884.92 | 20.57 | 0.23% |
| HKSE | 23,851.06 | 184.32 | -0.77% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,665.93 | 507.16 | -1.33% |
| NZX 50 Index | 12,538.16 | 110.94 | -0.88% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,545.70 | 19.40 | -0.23% |
| SSE Composite Index | 3,375.69 | 26.97 | -0.79% |